• Something wrong with this record ?

Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy

M. Jirásko, R. Viták, L. Pecen, A. Pinkeová, J. Tkáč, T. Bertók, N. Bergman, R. Kučera

. 2025 ; 85 (1) : 65-72. [pub] 20240927

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25002918

Grant support
"COOPERATIO" Program, research area Pharmaceutical Sciences
project BBMRI. cz, reg. no. LM2023033
Faculty Hospital in Pilsen-FNPl, 00669806

BACKGROUND: The medication used to treat benign prostate hyperplasia (BPH), a common condition in men over 50 years of age, can alter the levels of biomarkers used in prostate cancer detection. Commonly used medications for BPH include alpha-blockers, 5-alpha reductase inhibitors (5-ARIs), and muscarinic antagonists. We studied the impact of these drugs on total prostate-specific antigen (tPSA), free PSA (fPSA), [-2]proPSA, fPSA/tPSA ratio, and the Prostate Health Index (PHI), as well as novel potential biomarkers in the form of glycan composition of fPSA. PATIENTS AND METHODS: Serum samples were collected from 564 males with BPH, with a mean age of 68.5 years. The samples were used to measure levels of tPSA, fPSA, and [-2]proPSA. The fPSA/tPSA and PHI were then calculated. The glycan composition of fPSA was analyzed using lectin-based glycoprofiling. Pharmacotherapy data was collected from the patients' medical records. RESULTS: Alpha-blocker monotherapy was associated with higher fPSA and fPSA/tPSA ratio, and decreased PHI. Levels of tPSA were not impacted. Alpha-blocker and 5-ARI dual therapy was associated with reduced levels of fPSA, [-2]proPSA, and PHI. Therapy combining alpha-blockers and antimuscarinic agents did not significantly influence biomarker levels apart from an increase in a Maackia amurensis lectin-recognized glycan originating in fPSA. CONCLUSION: BPH pharmacotherapy notably affects prostate cancer biomarkers. Recognizing the impact of pharmacotherapy is crucial for achieving an accurate diagnosis of prostate cancer and for planning treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002918
003      
CZ-PrNML
005      
20250206103939.0
007      
ta
008      
250121s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pros.24801 $2 doi
035    __
$a (PubMed)39327946
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jirásko, Michal $u Department of Pharmacology and Toxicology, Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic $u Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic $1 https://orcid.org/0000000248747723
245    10
$a Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy / $c M. Jirásko, R. Viták, L. Pecen, A. Pinkeová, J. Tkáč, T. Bertók, N. Bergman, R. Kučera
520    9_
$a BACKGROUND: The medication used to treat benign prostate hyperplasia (BPH), a common condition in men over 50 years of age, can alter the levels of biomarkers used in prostate cancer detection. Commonly used medications for BPH include alpha-blockers, 5-alpha reductase inhibitors (5-ARIs), and muscarinic antagonists. We studied the impact of these drugs on total prostate-specific antigen (tPSA), free PSA (fPSA), [-2]proPSA, fPSA/tPSA ratio, and the Prostate Health Index (PHI), as well as novel potential biomarkers in the form of glycan composition of fPSA. PATIENTS AND METHODS: Serum samples were collected from 564 males with BPH, with a mean age of 68.5 years. The samples were used to measure levels of tPSA, fPSA, and [-2]proPSA. The fPSA/tPSA and PHI were then calculated. The glycan composition of fPSA was analyzed using lectin-based glycoprofiling. Pharmacotherapy data was collected from the patients' medical records. RESULTS: Alpha-blocker monotherapy was associated with higher fPSA and fPSA/tPSA ratio, and decreased PHI. Levels of tPSA were not impacted. Alpha-blocker and 5-ARI dual therapy was associated with reduced levels of fPSA, [-2]proPSA, and PHI. Therapy combining alpha-blockers and antimuscarinic agents did not significantly influence biomarker levels apart from an increase in a Maackia amurensis lectin-recognized glycan originating in fPSA. CONCLUSION: BPH pharmacotherapy notably affects prostate cancer biomarkers. Recognizing the impact of pharmacotherapy is crucial for achieving an accurate diagnosis of prostate cancer and for planning treatment.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a prostatický specifický antigen $x krev $7 D017430
650    12
$a hyperplazie prostaty $x krev $x farmakoterapie $7 D011470
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    12
$a antagonisté muskarinových receptorů $x terapeutické užití $7 D018727
650    _2
$a glykosylace $7 D006031
650    _2
$a alfa blokátory $x terapeutické užití $7 D000317
650    _2
$a inhibitory 5-alfa-reduktasy $x terapeutické užití $7 D058891
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a prostata $x patologie $x metabolismus $7 D011467
650    _2
$a nádory prostaty $x krev $x farmakoterapie $7 D011471
655    _2
$a časopisecké články $7 D016428
700    1_
$a Viták, Roman $u Department of Pharmacology and Toxicology, Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic $1 https://orcid.org/0009000928952541
700    1_
$a Pecen, Ladislav $u Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic
700    1_
$a Pinkeová, Andrea $u Glycanostics, Ltd., Kudlakova 7, Bratislava 841 01, Slovak Republic $u Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, 845 38, Bratislava, Slovak Republic $1 https://orcid.org/0009000813210580
700    1_
$a Tkáč, Jan $u Glycanostics, Ltd., Kudlakova 7, Bratislava 841 01, Slovak Republic
700    1_
$a Bertók, Tomáš $u Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, 845 38, Bratislava, Slovak Republic
700    1_
$a Bergman, Natalie $u Department of Pharmacology and Toxicology, Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic
700    1_
$a Kučera, Radek $u Department of Pharmacology and Toxicology, Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic $u Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic
773    0_
$w MED00010484 $t The Prostate $x 1097-0045 $g Roč. 85, č. 1 (2025), s. 65-72
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39327946 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103935 $b ABA008
999    __
$a ok $b bmc $g 2262983 $s 1238925
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 85 $c 1 $d 65-72 $e 20240927 $i 1097-0045 $m The Prostate $n Prostate $x MED00010484
GRA    __
$p "COOPERATIO" Program, research area Pharmaceutical Sciences
GRA    __
$p project BBMRI. cz, reg. no. LM2023033
GRA    __
$p Faculty Hospital in Pilsen-FNPl, 00669806
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options